LIVIVO - Search results -

Search results

Result 1 - 10 of total 163

Search options

Article ; Online: T-cell agents in the treatment of rheumatoid arthritis - 2012 update.

Solomon, Gary E

Bulletin of the NYU hospital for joint diseases

2012 Volume 70, Issue 3, Page(s) 191–194

MeSH term(s)	Abatacept ; Animals ; Antirheumatic Agents/adverse effects ; Antirheumatic Agents/therapeutic use ; Arthritis, Rheumatoid/diagnosis ; Arthritis, Rheumatoid/drug therapy ; Arthritis, Rheumatoid/immunology ; Biological Products/adverse effects ; Biological Products/therapeutic use ; Humans ; Immunoconjugates/adverse effects ; Immunoconjugates/therapeutic use ; T-Lymphocytes/drug effects ; T-Lymphocytes/immunology ; Treatment Outcome
Chemical Substances	Antirheumatic Agents ; Biological Products ; Immunoconjugates ; Abatacept (7D0YB67S97)
Language	English
Publishing date	2012
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	390411-8
ISSN	1936-9727 ; 2328-5273 ; 1936-9719 ; 0018-5647 ; 0883-9344 ; 2328-4633
ISSN (online)	1936-9727 ; 2328-5273
ISSN	1936-9719 ; 0018-5647 ; 0883-9344 ; 2328-4633
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Uk I Zs.233: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: T-cell agents in the treatment of rheumatoid arthritis - 2011 update.

Solomon, Gary E

Bulletin of the NYU hospital for joint diseases

2011 Volume 69, Issue 3, Page(s) 230–232

MeSH term(s)	Abatacept ; Antirheumatic Agents/adverse effects ; Antirheumatic Agents/therapeutic use ; Arthritis, Rheumatoid/drug therapy ; Arthritis, Rheumatoid/immunology ; Humans ; Immunoconjugates/adverse effects ; Immunoconjugates/therapeutic use ; T-Lymphocytes/drug effects ; T-Lymphocytes/immunology ; Treatment Outcome
Chemical Substances	Antirheumatic Agents ; Immunoconjugates ; Abatacept (7D0YB67S97)
Language	English
Publishing date	2011
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	390411-8
ISSN	1936-9727 ; 2328-5273 ; 1936-9719 ; 0018-5647 ; 0883-9344 ; 2328-4633
ISSN (online)	1936-9727 ; 2328-5273
ISSN	1936-9719 ; 0018-5647 ; 0883-9344 ; 2328-4633
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Uk I Zs.233: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Synthesizing the links between secure housing tenure and health for more equitable cities.

Baumgartner, Jill / Rodriguez, Judith / Berkhout, Frans / Doyle, Yvonne / Ezzati, Majid / Owuso, George / Quayyum, Zahidul / Solomon, Bethlehem / Winters, Meghan / Adamkiewicz, Gary / Robinson, Brian E

Wellcome open research

2023 Volume 7, Page(s) 18

Abstract: ... from their homes or the land on which they live (i.e., lack secure tenure), and the urban poor are most vulnerable ...

Abstract	Millions of households in rich and poor countries alike are at risk of being unwilfully displaced from their homes or the land on which they live (i.e., lack secure tenure), and the urban poor are most vulnerable. Improving housing tenure security may be an intervention to improve housing and environmental conditions and reduce urban health inequalities. Building on stakeholder workshops and a narrative review of the literature, we developed a conceptual model that infers the mechanisms through which more secure housing tenure can improve housing, environmental quality, and health. Empirical studies show that more secure urban housing tenure can boost economic mobility, improve housing and environmental conditions including reduced exposure to pollution, create safer and more resourced communities, and improve physical and mental health. These links are shared across tenure renters and owners and different economic settings. Broader support is needed for context-appropriate policies and actions to improve tenure security as a catalyst for cultivating healthier homes and neighbourhoods and reducing urban health inequalities in cities.
Language	English
Publishing date	2023-03-13
Publishing country	England
Document type	Journal Article
ISSN	2398-502X
ISSN	2398-502X
DOI	10.12688/wellcomeopenres.17244.2
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: T-cell agents in the treatment of rheumatoid arthritis.

Solomon, Gary E

Bulletin of the NYU hospital for joint diseases

2010 Volume 68, Issue 3, Page(s) 162–165

Abstract: T cells play a prominent role in the pathogenesis of rheumatoid arthritis. Abatacept is the first FDA approved agent for rheumatoid arthritis that blocks the activation of T cells by interrupting the interaction between the CD28 ligand on the T cell and ... ...

Abstract	T cells play a prominent role in the pathogenesis of rheumatoid arthritis. Abatacept is the first FDA approved agent for rheumatoid arthritis that blocks the activation of T cells by interrupting the interaction between the CD28 ligand on the T cell and the CD80/86 ligand on the antigen presenting cell. Inhibition of T cell activation has pleotropic effects that lowers the downstream production of multiple cytokines. In clinical trials, abatacept is effective in treating the signs and symptoms of rheumatoid arthritis as well as in inhibiting structural damage. It has a favorable safety profile and can be used in patients who may have comorbidities that preclude the use of anti-TNF agents. While no direct head to head trials exist, a study in which both abatacept and infiximab were compared to an identical control population, suggested that the efficacy of the two drugs was similar but that there were fewer adverse effects with abatacept than with infiximab. Abatacept is an important addition to the therapeutic repertoire available to treat rheumatoid arthritis. Available data support its use as a first line agent to treat patients who have had and inadequate response to methotrexate.
MeSH term(s)	Abatacept ; Antibodies, Monoclonal/adverse effects ; Antibodies, Monoclonal/therapeutic use ; Antirheumatic Agents/adverse effects ; Antirheumatic Agents/therapeutic use ; Arthritis, Rheumatoid/drug therapy ; Arthritis, Rheumatoid/immunology ; Humans ; Immunoconjugates/adverse effects ; Immunoconjugates/therapeutic use ; Infliximab ; Lymphocyte Activation/drug effects ; T-Lymphocytes/drug effects ; T-Lymphocytes/immunology ; Treatment Outcome
Chemical Substances	Antibodies, Monoclonal ; Antirheumatic Agents ; Immunoconjugates ; Abatacept (7D0YB67S97) ; Infliximab (B72HH48FLU)
Language	English
Publishing date	2010
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	390411-8
ISSN	1936-9727 ; 2328-5273 ; 1936-9719 ; 0018-5647 ; 0883-9344 ; 2328-4633
ISSN (online)	1936-9727 ; 2328-5273
ISSN	1936-9719 ; 0018-5647 ; 0883-9344 ; 2328-4633
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Uk I Zs.233: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Discovery Proteomics Analysis Determines That Driver Oncogenes Suppress Antiviral Defense Pathways Through Reduction in Interferon-β Autocrine Stimulation.

Solomon, Paige E / Kirkemo, Lisa L / Wilson, Gary M / Leung, Kevin K / Almond, Mark H / Sayles, Leanne C / Sweet-Cordero, E Alejandro / Rosenberg, Oren S / Coon, Joshua J / Wells, James A

Molecular & cellular proteomics : MCP

2022 Volume 21, Issue 7, Page(s) 100247

Abstract: Since the discovery of oncogenes, there has been tremendous interest to understand their mechanistic basis and to develop broadly actionable therapeutics. Some of the most frequently activated oncogenes driving diverse cancers are c-MYC, EGFR, HER2, AKT, ...

Abstract	Since the discovery of oncogenes, there has been tremendous interest to understand their mechanistic basis and to develop broadly actionable therapeutics. Some of the most frequently activated oncogenes driving diverse cancers are c-MYC, EGFR, HER2, AKT, KRAS, BRAF, and MEK. Using a reductionist approach, we explored how cellular proteomes are remodeled in isogenic cell lines engineered with or without these driver oncogenes. The most striking discovery for all oncogenic models was the systematic downregulation of scores of antiviral proteins regulated by type 1 interferon. These findings extended to cancer cell lines and patient-derived xenograft models of highly refractory pancreatic cancer and osteosarcoma driven by KRAS and MYC oncogenes. The oncogenes reduced basal expression of and autocrine stimulation by type 1 interferon causing remarkable convergence on common phenotypic and functional profiles. In particular, there was dramatically lower expression of dsRNA sensors including DDX58 (RIG-I) and OAS proteins, which resulted in attenuated functional responses when the oncogenic cells were treated with the dsRNA mimetic, polyI:C, and increased susceptibility to infection with an RNA virus shown using SARS-CoV-2. Our reductionist approach provides molecular and functional insights connected to immune evasion hallmarks in cancers and suggests therapeutic opportunities.
MeSH term(s)	Animals ; Antiviral Restriction Factors ; COVID-19/immunology ; Carcinogenesis ; Cell Line, Tumor ; Humans ; Interferon-beta/immunology ; Oncogenes ; Proteomics ; Proto-Oncogene Proteins p21(ras)/genetics ; SARS-CoV-2
Chemical Substances	Antiviral Restriction Factors ; Interferon-beta (77238-31-4) ; Proto-Oncogene Proteins p21(ras) (EC 3.6.5.2)
Language	English
Publishing date	2022-05-18
Publishing country	United States
Document type	Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
ZDB-ID	2075924-1
ISSN	1535-9484 ; 1535-9476
ISSN (online)	1535-9484
ISSN	1535-9476
DOI	10.1016/j.mcpro.2022.100247
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5599: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Psychometric Properties of Computerized Cognitive Tools and Standard Neuropsychological Tests Used to Assess Sport Concussion: A Systematic Review.

Wilmoth, Kristin / Brett, Benjamin L / Emmert, Natalie A / Cook, Carolyn M / Schaffert, Jeffrey / Caze, Todd / Kotsonis, Thomas / Cusick, Margaret / Solomon, Gary / Resch, Jacob E / Cullum, C Munro / Nelson, Lindsay D / McCrea, Michael

Neuropsychology review

2022 Volume 33, Issue 4, Page(s) 675–692

Abstract: ... if they evaluated psychometric properties (e.g., reliability, sensitivity) of a cognitive assessment within pure ...

Abstract	Athletic programs are more frequently turning to computerized cognitive tools in order to increase efficiencies in concussion assessment. However, assessment using a traditional neuropsychological test battery may provide a more comprehensive and individualized evaluation. Our goal was to inform sport clinicians of the best practices for concussion assessment through a systematic literature review describing the psychometric properties of standard neuropsychological tests and computerized tools. We conducted our search in relevant databases including Ovid Medline, Web of Science, PsycINFO, and Scopus. Journal articles were included if they evaluated psychometric properties (e.g., reliability, sensitivity) of a cognitive assessment within pure athlete samples (up to 30 days post-injury). Searches yielded 4,758 unique results. Ultimately, 103 articles met inclusion criteria, all of which focused on adolescent or young adult participants. Test-retest reliability estimates ranged from .14 to .93 for computerized tools and .02 to .95 for standard neuropsychological tests, with strongest correlations on processing speed tasks for both modalities, although processing speed tasks were most susceptible to practice effects. Reliability was improved with a 2-factor model (processing speed and memory) and by aggregating multiple baseline exams, yet remained below acceptable limits for some studies. Sensitivity to decreased cognitive performance within 72 h of injury ranged from 45%-93% for computerized tools and 18%-80% for standard neuropsychological test batteries. The method for classifying cognitive decline (normative comparison, reliable change indices, regression-based methods) affected sensitivity estimates. Combining computerized tools and standard neuropsychological tests with the strongest psychometric performance provides the greatest value in clinical assessment. To this end, future studies should evaluate the efficacy of hybrid test batteries comprised of top-performing measures from both modalities.
MeSH term(s)	Adolescent ; Young Adult ; Humans ; Athletic Injuries/diagnosis ; Reproducibility of Results ; Psychometrics ; Brain Concussion/diagnosis ; Brain Concussion/psychology ; Neuropsychological Tests ; Sports ; Cognition
Language	English
Publishing date	2022-08-30
Publishing country	United States
Document type	Systematic Review ; Journal Article ; Review
ZDB-ID	1062572-0
ISSN	1573-6660 ; 1040-7308
ISSN (online)	1573-6660
ISSN	1040-7308
DOI	10.1007/s11065-022-09553-4
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 3116: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Older adults with newly diagnosed high-risk/secondary AML who achieved remission with CPX-351: phase 3 post hoc analyses.

Lin, Tara L / Rizzieri, David A / Ryan, Daniel H / Schiller, Gary J / Kolitz, Jonathan E / Uy, Geoffrey L / Hogge, Donna E / Solomon, Scott R / Wieduwilt, Matthew J / Ryan, Robert J / Faderl, Stefan / Cortes, Jorge E / Lancet, Jeffrey E

Blood advances

2021 Volume 5, Issue 6, Page(s) 1719–1728

Abstract: CPX-351, a dual-drug liposomal encapsulation of daunorubicin/cytarabine in a synergistic 1:5 molar ratio, is approved for the treatment of adults with newly diagnosed, therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related ... ...

Abstract	CPX-351, a dual-drug liposomal encapsulation of daunorubicin/cytarabine in a synergistic 1:5 molar ratio, is approved for the treatment of adults with newly diagnosed, therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC). In a pivotal phase 3 study, patients aged 60 to 75 years with newly diagnosed, high-risk/secondary AML were randomized to receive CPX-351 or conventional 7+3 chemotherapy. In the primary endpoint analysis, CPX-351 demonstrated significantly prolonged median overall survival (OS) vs 7+3. These exploratory post hoc subgroup analyses evaluated the impact of achieving complete remission (CR) or CR with incomplete neutrophil or platelet recovery (CRi) with CPX-351 (73/153 [48%]) vs conventional 7+3 (52/56 [33%]) on outcomes. CPX-351 improved median OS vs 7+3 in patients who achieved CR or CRi (25.43 vs 10.41 months; hazard ratio = 0.49; 95% confidence interval, 0.31, 0.77). Improved median OS was seen across AML subtypes (t-AML, AML-MRC), age subgroups (60 to 69 vs 70 to 75 years), patients with prior hypomethylating agent exposure, and patients who did not undergo transplantation. Patients who achieved CR or CRi with CPX-351 also had a higher rate of transplantation, a longer median OS landmarked from the date of transplantation (not reached vs 11.65 months; hazard ratio = 0.43; 95% confidence interval, 0.21, 0.89), and a safety profile that was consistent with the known safety profile of 7+3. These results suggest deeper remissions may be achieved with CPX-351, leading to improved OS. This study was registered at www.clinicaltrials.gov as #NCT01696084.
MeSH term(s)	Aged ; Cytarabine ; Daunorubicin ; Humans ; Leukemia, Myeloid, Acute/drug therapy ; Middle Aged ; Myelodysplastic Syndromes
Chemical Substances	CPX-351 ; Cytarabine (04079A1RDZ) ; Daunorubicin (ZS7284E0ZP)
Language	English
Publishing date	2021-03-16
Publishing country	United States
Document type	Clinical Trial, Phase III ; Journal Article ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
ZDB-ID	2915908-8
ISSN	2473-9537 ; 2473-9529
ISSN (online)	2473-9537
ISSN	2473-9529
DOI	10.1182/bloodadvances.2020003510
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 7153: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: A phase II trial of gemcitabine and erlotinib followed by ChemoProton therapy plus capecitabine and oxaliplatin for locally advanced pancreatic cancer.

Sanghvi, Samrat M / Coffman, Alex R / Hsueh, Chung-Tsen / Kang, Joseph / Park, Annie / Solomon, Naveenraj L / Garberoglio, Carlos A / Reeves, Mark E / Slater, Jerry D / Yang, Gary Y

Journal of gastrointestinal oncology

2022 Volume 13, Issue 4, Page(s) 1989–1996

Abstract: Background: Epidermal growth factor receptor (EGFR) is overexpressed in pancreatic cancer. EGFR expression plays a potentially important role in modulation of tumor sensitivity to either chemotherapy or radiotherapy. Erlotinib is a receptor tyrosine ... ...

Abstract	Background: Epidermal growth factor receptor (EGFR) is overexpressed in pancreatic cancer. EGFR expression plays a potentially important role in modulation of tumor sensitivity to either chemotherapy or radiotherapy. Erlotinib is a receptor tyrosine kinase inhibitor with specificity for EGFR/HER1. A phase II trial was conducted to explore the efficacy of a regimen utilizing erlotinib and proton therapy. Methods: Patients with unresectable or borderline resectable non-metastatic adenocarcinoma of the pancreas were included. Patients received 8-week systemic treatment with gemcitabine 1,000 mg/m Results: The study enrolled 9 patients ages 47-81 years old (median 62) between January 2013 and March 2016, when the trial was closed due to low patient accrual. The 1-year OS rate was 55.6% (95% CI: 31% to 99%). The median OS was 14.1 months (95% CI: 11.4-NE) and the median PFS was 10.8 months (95% CI: 7.44-NE). A majority of patients completed CPT and GE, but only 33.3% completed the four cycles of CapOx. A third of patients experienced grade 3 toxicities, which were all hepatic along with one patient who also had grade 3 diarrhea. There were no grade 4 or 5 toxicities. Four patients were enrolled with borderline resectable disease, three of which were eligible for pancreaticoduodenectomy after GE and CPT treatment. One of two patients who underwent resection had a negative margin. Conclusions: This regimen for locally advanced pancreatic cancer (LAPC) exceeded the pre-specified benchmark and was safe and well tolerated. Additional investigations utilizing more current systemic treatment regimens with proton therapy are warranted. Trial registration: ClinicalTrials.gov identifier (NCTNCT01683422).
Language	English
Publishing date	2022-09-02
Publishing country	China
Document type	Journal Article
ZDB-ID	2594644-4
ISSN	2219-679X ; 2078-6891
ISSN (online)	2219-679X
ISSN	2078-6891
DOI	10.21037/jgo-22-327
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Treatment Factors Associated With Overall Survival in Retroperitoneal Sarcoma: An Institutional Review.

Kwong, Mei L / Lee, Becky / Kunihira, Karissa / Sutjiadi, Brian / Reeves, Mark E / Selleck, Matthew / Yang, Gary / Solomon, Naveenraj

The American surgeon

2020 Volume 86, Issue 10, Page(s) 1358–1362

Abstract: Introduction: Retroperitoneal sarcoma (RPS) is a rare malignancy, and curative resection is considered the main therapy. Use of chemotherapy and/or radiation in addition to surgery (multimodality therapy) is controversial.: Objective: To determine ... ...

Abstract	Introduction: Retroperitoneal sarcoma (RPS) is a rare malignancy, and curative resection is considered the main therapy. Use of chemotherapy and/or radiation in addition to surgery (multimodality therapy) is controversial. Objective: To determine treatment factors that influence overall survival in RPS. Methods: This retrospective Institutional Review Board-approved study identified patients with RPS treated at a single institution between 2000 and 2017. Patient, tumor, and treatment modalities were collected. Prism (v.8.2.1) was used to calculate Kaplan-Meier survival curves. Results: There were 695 patients with sarcoma between 2000 and 2017, and 61 adults had RPS. The mean age was 59 (range 31-86) years, with 57.4% females (n = 35). Patients were 68.9% Caucasian (n = 42), 21.3% Hispanic (n = 13), 8.2% black (n = 5), and 1.6% Asian (n = 1). There were 4 patients who had neoadjuvant therapy (chemotherapy, n = 3; radiation, n = 2) and 17 who had adjuvant therapy (chemotherapy, n = 6; radiation, n = 14). There was no significant difference in survival between the groups who received multimodality therapy compared to surgery alone. There was a significant improvement in the median overall survival for patients who underwent one or multiple surgeries ( Conclusions: These institutional data suggest that treatment factors associated with overall survival included multiple resections. Use of multimodality therapy was low and did not influence overall survival in patients with RPS compared to surgery alone.
MeSH term(s)	Adult ; Aged ; Aged, 80 and over ; Combined Modality Therapy ; Female ; Humans ; Male ; Middle Aged ; Retroperitoneal Neoplasms/mortality ; Retroperitoneal Neoplasms/surgery ; Retrospective Studies ; Sarcoma/mortality ; Sarcoma/surgery ; Survival Analysis
Language	English
Publishing date	2020-10-30
Publishing country	United States
Document type	Journal Article
ZDB-ID	202465-2
ISSN	1555-9823 ; 0003-1348
ISSN (online)	1555-9823
ISSN	0003-1348
DOI	10.1177/0003134820964460
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Uk I Zs.106: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Collaborative research among academia, business, and government.

Chapman, Peter M / Brain, Richard A / Belden, Jason B / Forbes, Valery E / Mebane, Christopher A / Hoke, Robert A / Ankley, Gary T / Solomon, Keith R

Integrated environmental assessment and management

2018 Volume 14, Issue 1, Page(s) 152–154

Language	English
Publishing date	2018-01
Publishing country	United States
Document type	Journal Article
ZDB-ID	2234931-5
ISSN	1551-3793 ; 1551-3777
ISSN (online)	1551-3793
ISSN	1551-3777
DOI	10.1002/ieam.1975
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Bonn / Germany

Z 7647: Show issues

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Bonn / Germany

Order via subito

Inter-library loan at ZB MED